Fåhraeus Startup & Growth Fund II invests €5 million in Fida Biosystems to advance its biophysical analysis technology and support international expansion.
Information on the Target
Fida Biosystems is a pioneering Danish life science tools company dedicated to developing advanced biophysical analysis platforms. These platforms enable faster and more accurate characterization of molecules and nanoparticles, which is pivotal in the creation of new medicines. Over the past year, Fida has demonstrated remarkable growth, doubling its revenue and achieving significant market adoption with over 100 instruments sold to leading research institutions and various industries.
The company employs proprietary technology known as Flow Induced Dispersion Analysis (FIDA), which facilitates rapid and precise analysis of biomolecules and nanoparticles directly within complex biological samples. This cutting-edge approach empowers biotech and pharmaceutical companies to better comprehend molecular behavior, thereby expediting drug development processes.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Denmark
Denmark boasts a robust life sciences sector, characterized by a high level of innovation and collaboration between research institutions and industry players. The country ran
Similar Deals
Fåhraeus Startup & Growth Fund II (FSG)
invested in
Fida Biosystems
in 2025
in a Series A deal
Disclosed details
Transaction Size: $5M